View Older Stories View More Recent Stories

Feb 24, 2022 06:14AM Stifel Reiterates Allogene (ALLO) at Hold, Competitive Pressures Could Present Short-term Headwinds for Shares

Feb 24, 2022 06:00AM Mizuho Securities Reiterates Buy Rating on Xencor (XNCR), Sees Multiple Opportunities

Feb 24, 2022 05:58AM Insulet Corporation (PODD) PT Slashed to $250 at Stifel, but Analyst Remains Bullish on Multiple Upcoming Catalysts

Feb 24, 2022 05:56AM Global Blood Therapeutics (GBT) PT Lowered to $65 at Stifel, Expect Near Term Sentiment to be Dominated by Fulcrum's FTX-6058 Data

Feb 24, 2022 05:40AM Raymond James Reiterates Global Blood Therapeutics (GBT) at Market Perform, Concerns Over Oxbryta’s Long Term Potential Remain

Feb 24, 2022 05:38AM Stifel Reiterates BioMarin Pharmaceutical (BMRN) at Buy, Believes the Stock Can Outperform on Strong Voxogo Launch and Roctavian Approvals

Feb 24, 2022 05:34AM Mizuho Securities Reiterates Arcus Biosciences (RCUS) at Buy, Sees Disconnect Between Company's Prospects and Current Valuation

Feb 24, 2022 05:31AM Cowen Reiterates Outperform Rating on Allogene (ALLO), "We Recommend Accumulating ALLO Shares"

Feb 23, 2022 02:15PM G1 Therapeutics (GTHX) Reiterated at Outperform by Cowen, Expect Shares to Outperform as Phase 3 Readout Approaches

Feb 23, 2022 10:35AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Feb 23, 2022 09:44AM Dawson James Reiterates Neutral Rating on Celsion Corp (CLSN), Believes GEN-1's Probability of Success is Only 10%

Feb 23, 2022 09:06AM Stifel Reiterates Hold Rating on Tandem Diabetes Care (TNDM), Warns the Increasingly Competitive Environment May Decelerate Growth

Feb 23, 2022 08:08AM Mizuho Reiterates Relmada (RLMD) at Buy, REL-1017 Setting Up for Meaningful Commercial Opportunity, Peak Sales Estimated at $1.03B

Feb 23, 2022 07:42AM H.C. Wainwright Reiterates Buy Rating on Albireo Pharma (ALBO), Estimates Peak Bylvay PFIC Sales of $446M

Feb 23, 2022 05:45AM Arcutis (ARQT) Reiterated at Overweight by Cantor Fitzgerald, Company's Opportunity to Become Medical Dermatology Leader Remains Underappreciated

Feb 23, 2022 05:43AM Marinus Pharmaceuticals (MRNS) PT Lowered to $35 at Truist Securities on Trial Delay, Analyst Maintains Confidence in Ganaxolone

Feb 23, 2022 05:40AM Cantor Fitzgerald Reiterates Cutera (CUTR) at Overweight, Company's Comprehensive Portfolio of Innovative Solutions is Underappreciated, Expect Upward Earnings Revisions

Feb 23, 2022 05:38AM Apollo Endosurgery (APEN) PT Lowered to $10 at Stifel on Market Multiple Compression, but Multiple Growth Drivers Should Drive Sustained Expansion

Feb 23, 2022 05:34AM Cowen Reiterates PTC Therapeutics (PTCT) at Market Perform, Upcoming Quarters Will Determine Company's Trajectory

Feb 23, 2022 05:31AM Stifel Reiterates Buy Rating on Cerus (CERS), Latest Results Increase Confidence in the Company's Business Model

Feb 23, 2022 05:29AM Marinus (MRNS) Reiterated at Outperform by Cowen, RAISE Delay is Unfortunate, but Shares Undervalued on ganaxolone Potential

Feb 22, 2022 03:50PM Akebia Therapeutics (AKBA) Reiterated at Buy by Needham & Company, New Vifor Partnership is a Vote of Confidence Ahead of FDA Decision

Feb 22, 2022 03:43PM Truist Securities Reiterates Gilead Sciences (GILD) at Hold, Stock Presents Attractive Opportunity for Long-term Investors

Feb 22, 2022 03:02PM Cantor Fitzgerald Reiterates Novan (NOVN) at Overweight, Peak Sales of SB206 Underappreciated, Expect Upwards Earnings Revisions

Feb 22, 2022 02:15PM Cowen Reiterates Esperion Therapeutics (ESPR) at Outperform, CLEAR Outcomes Study Results Could be an Inflection Point for Sales

Feb 22, 2022 12:03PM Esperion Therapeutics (ESPR) Reiterated at Buy by Needham & Company, Expect Nexletol/Nexlizet to Deliver Important Sales Growth, but Focus Remains on CLEAR Trial Results

Feb 22, 2022 05:48AM Needham & Company Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL), Believes FDA Decision on FT218 Could be Coming Soon

Feb 18, 2022 11:11AM Raymond James Reiterates Agios Pharma (AGIO) at Market Perform, Continues to Expect a Very Slow Launch, Stock Will Trade Range-Bound Until There is Meaningful Revenue

Feb 18, 2022 10:16AM Atara Biotherapeutics (ATRA) Reiterated at Buy by Stifel, Fatal SAE is Disappointing, but Ultimately ATA188 Should Dominate the Sentiment

Feb 18, 2022 06:19AM H.C. Wainwright Reiterates Buy Rating on Mustang Bio (MBIO), MB-102 Opportunity Remains Key

Feb 18, 2022 06:11AM Ligand (LGND) Reiterated at Buy by H.C. Wainwright, Strong Partnerships and Cash Position Should Drive Future Value

Feb 18, 2022 05:47AM Globus Medical (GMED) PT Lowered to $70 at Stifel, Challenging January and Delayed Excelsius3D Roll-out to Weigh In on Shares, but Expect Upside Later in the Year

Feb 18, 2022 05:42AM Truist Securities Reiterates Buy Rating on Arvinas (ARVN), bavdeglutamide Data Matures and Shows Sufficient Evidence of Efficacy and Safety

Feb 17, 2022 04:51PM Insmed (INSM) PT Slashed to $53 at Cantor Fitzgerald, Lower Sales Forecast for Arikayce and Increased OpEx Weigh In

Feb 17, 2022 11:37AM Cowen Reiterates Arvinas (ARVN) at Outperform, Street Should Start Ascribing Value to Bavdegalutamide Program

Feb 17, 2022 05:55AM Johnson & Johnson (JNJ), Cidara Therapeutics (CDTX), Pfizer (PFE), and PDS Biotechnology (PDSB) - Cantor Fitzgerald's Top Flu Vaccine Candidates for 2022

Feb 16, 2022 05:12PM Stifel Reiterates Buy Rating on Eliem Therapeutics Inc. (ELYM), Analyst Remains Optimistic on Prospects of ETX-810

Feb 16, 2022 12:57PM Stifel Reiterates Hold Rating on Alkermes (ALKS), Company Remains Confident in Long-Term Profitability Trajectory

Feb 16, 2022 11:26AM Stifel Reiterates Equillium (EQ) at Buy, Initial Take on Bioniz Acquisition is Positive, May Generate Extensive Synergies, All-Stock Transaction is Logica

Feb 16, 2022 09:54AM Spero Therapeutics (SPRO) Reiterated at Overweight by Cantor Fitzgerald, SPR206 Results Support Further Development, Expect Upward Earnings Revisions and Multiple Expansion

Feb 16, 2022 09:50AM Stifel Reiterates Reiterates Sage Therapeutics (SAGE) at Buy, Zuranolone is An Approvable Product, But Durability of Benefit and Commercial Positioning Remain Debatable

Feb 16, 2022 09:07AM Biogen (BIIB) Reiterated at Market Perform by BMO Capital, Zuranolone Looks Approvable in MDD, but Incremental Positive Doesn't Change Challenging Narrative Around Biogen

Feb 16, 2022 08:22AM 22nd Century Group (XXII) Reiterated at Buy by Dawson James, New FDA Commissioner Expected to Move Forward on Low-Nicotine Mandate & Drive the Company's Value

Feb 16, 2022 07:55AM Needham & Company Reiterates Sage Therapeutics (SAGE) at Buy, but Expects Stock to be Down on Day 15 Endpoint Miss

Feb 16, 2022 06:23AM Needham & Company Reiterates Buy Rating on CRISPR Therapeutics (CRSP), Foray Into Regenerative Medicine offers Large Market Potential

Feb 16, 2022 06:19AM William Blair Reiterates Market Perform Rating on Allakos Inc. (ALLK), lirentelimab May Still Have Path for Approval in EGIDs

Feb 16, 2022 06:17AM Needham & Company Reiterates Cytokinetics (CYTK) at Buy, Sees no Impact from METEORIC-HF Fail on Potential FDA Approval

Feb 16, 2022 06:13AM Needham & Company Reiterates Buy Rating, $84 PT on Pacira Pharmaceuticals (PCRX), Continue to Expect Significant Sales Growth Rebound

Feb 16, 2022 06:11AM Biogen (BIIB) PT Slashed to $320 at Truist Securities on Lower COGS, Maintained at Buy, Focus Remains on lecanemab

Feb 16, 2022 06:09AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD) Going into Virology Deep Dive Event

View More Recent Stories View Older Stories